Aktienanalyse zu Alector, Inc. (ALEC)ALECAlector, Inc.

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Alector Inc (ALEC) is a good buy right now due to its current price of $2.15, which is significantly below the analyst price target of $3, indicating a potential upside of about 40%. Additionally, the stock has shown a strong year-to-date change of +40.52%, suggesting positive momentum. The RSI is currently at 61.68, indicating that the stock is not overbought yet, which is favorable for new investors. However, the main risk is the company's negative earnings per share (EPS) of -0.21, which reflects ongoing financial challenges.